### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

#### **BIOMARIN PHARMACEUTICAL INC**

Form 4

September 23, 2014

<b>FORM</b>	4 .
-------------	-----

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

burden hours per

response...

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average

0.5

**OMB APPROVAL** 

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

3ee msu 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Davis George Eric			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]					5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
(Last)  C/O BIOMA PHARMAC DIGITAL I	ARIN CEUTICAL INC.,	(	3. Date of Earliest Transaction (Month/Day/Year) 09/19/2014					Director 10% Owner X Officer (give title Other (specify below) SVP, General Counsel			
NOVATO,		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acqu	uired, Disposed of	, or Beneficiall	v Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution I any (Month/Da)	ed Date, if	3. Transactio Code (Instr. 8)	4. Securit	ies Ac sposed	quired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	5. Amount of 6. 7. Nature Ownership Indirect Beneficially Form: Direct Benefici Owned (D) or Ownersh Indirect (I) (Instr. 4) (Instr. 4) (Instr. 4)		
Common Stock	09/19/2014(1)	09/19/20	14	Code V M	Amount 17,536	(D)	Price \$ 21.51	(Instr. 3 and 4) 81,962	D		
Common Stock	09/19/2014(1)	09/19/20	14	S	17,536	D	\$ 69.75 (2)	64,426	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

number.

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisals Expiration Date (Month/Day/Year	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Stock Option (right to buy) Common Stock	\$ 69.75 (1)	09/19/2014	09/19/2014	M	17,536	11/12/2010(3)	05/11/2020	Common Stock	17,53

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Davis George Eric C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949

SVP, General Counsel

## **Signatures**

/s/ Laura Randall Woodhead, Attorney-in-Fact

09/23/2014

\*\*Signature of Reporting Person

Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pusuant to a Rule 10b5-1 trading place executed on August 25, 2014...
- (2) All shares sold at same price.
- (3) Original option grant vests 6/48ths on November 12, 2010 and 1/48th on the 12th day of every month thereafter
- (4) Reflects the number of stock options that reaming outstanding from this specific stock option grant following the reported transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2